Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing

Gerald L Denardo, Malik E. Juweid, Christine A. White, Gregory A. Wiseman, Sally J. DeNardo

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Cancer-seeking antibodies (Abs) carrying radionuclides can be powerful drugs for delivering radiotherapy to cancer. As with all radiotherapy, undesired radiation dose to critical organs is the limiting factor. It has been proposed that optimization of radioimmunotherapy (RIT), that is, maximization of therapeutic efficacy and minimization of normal tissue toxicity, depends on a foreknowledge of the radiation dose distributions to be expected. The necessary data can be acquired by established tracer techniques, in individual patients, using quantitative radionuclide imaging. Object-oriented software systems for estimating internal emitter radiation doses to the tissues of individual patients (patient-specific radiation dosimetry), using computer modules, are available for RIT, as well as for other radionuclide therapies. There is general agreement that radiation dosimetry (radiation absorbed dose distribution, cGy) should be utilized to establish the safety of RIT with a specific radiolabeled Ab in the early stages (i.e. phase I or II) of drug evaluation. However, it is less well established that radiation dose should be used to determine the radionuclide dose (amount of radioactivity, GBq) to be administered to a specific patient (i.e. radiation dose-based therapy). Although treatment planning for individual patients based upon tracer radiation dosimetry is an attractive concept and opportunity, particularly for multimodality RIT with intent to cure, practical considerations may dictate simpler solutions under some circumstances.

Original languageEnglish (US)
Pages (from-to)203-218
Number of pages16
JournalCritical Reviews in Oncology/Hematology
Volume39
Issue number1-2
DOIs
StatePublished - 2001

Fingerprint

Radiometry
Radioimmunotherapy
Radiation
Radioisotopes
Radiotherapy
Therapeutics
Drug Evaluation
Radionuclide Imaging
Radioactivity
Neoplasms
Software
Safety
Antibodies
Pharmaceutical Preparations

Keywords

  • Radiation dosimetry
  • Radioimmunotherapy
  • Radionuclide dose
  • Treatment dosing

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing. / Denardo, Gerald L; Juweid, Malik E.; White, Christine A.; Wiseman, Gregory A.; DeNardo, Sally J.

In: Critical Reviews in Oncology/Hematology, Vol. 39, No. 1-2, 2001, p. 203-218.

Research output: Contribution to journalArticle

Denardo, Gerald L ; Juweid, Malik E. ; White, Christine A. ; Wiseman, Gregory A. ; DeNardo, Sally J. / Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing. In: Critical Reviews in Oncology/Hematology. 2001 ; Vol. 39, No. 1-2. pp. 203-218.
@article{2d8f6d67ec95448f93b1b10fc9f48722,
title = "Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing",
abstract = "Cancer-seeking antibodies (Abs) carrying radionuclides can be powerful drugs for delivering radiotherapy to cancer. As with all radiotherapy, undesired radiation dose to critical organs is the limiting factor. It has been proposed that optimization of radioimmunotherapy (RIT), that is, maximization of therapeutic efficacy and minimization of normal tissue toxicity, depends on a foreknowledge of the radiation dose distributions to be expected. The necessary data can be acquired by established tracer techniques, in individual patients, using quantitative radionuclide imaging. Object-oriented software systems for estimating internal emitter radiation doses to the tissues of individual patients (patient-specific radiation dosimetry), using computer modules, are available for RIT, as well as for other radionuclide therapies. There is general agreement that radiation dosimetry (radiation absorbed dose distribution, cGy) should be utilized to establish the safety of RIT with a specific radiolabeled Ab in the early stages (i.e. phase I or II) of drug evaluation. However, it is less well established that radiation dose should be used to determine the radionuclide dose (amount of radioactivity, GBq) to be administered to a specific patient (i.e. radiation dose-based therapy). Although treatment planning for individual patients based upon tracer radiation dosimetry is an attractive concept and opportunity, particularly for multimodality RIT with intent to cure, practical considerations may dictate simpler solutions under some circumstances.",
keywords = "Radiation dosimetry, Radioimmunotherapy, Radionuclide dose, Treatment dosing",
author = "Denardo, {Gerald L} and Juweid, {Malik E.} and White, {Christine A.} and Wiseman, {Gregory A.} and DeNardo, {Sally J.}",
year = "2001",
doi = "10.1016/S1040-8428(01)00109-3",
language = "English (US)",
volume = "39",
pages = "203--218",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "1-2",

}

TY - JOUR

T1 - Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing

AU - Denardo, Gerald L

AU - Juweid, Malik E.

AU - White, Christine A.

AU - Wiseman, Gregory A.

AU - DeNardo, Sally J.

PY - 2001

Y1 - 2001

N2 - Cancer-seeking antibodies (Abs) carrying radionuclides can be powerful drugs for delivering radiotherapy to cancer. As with all radiotherapy, undesired radiation dose to critical organs is the limiting factor. It has been proposed that optimization of radioimmunotherapy (RIT), that is, maximization of therapeutic efficacy and minimization of normal tissue toxicity, depends on a foreknowledge of the radiation dose distributions to be expected. The necessary data can be acquired by established tracer techniques, in individual patients, using quantitative radionuclide imaging. Object-oriented software systems for estimating internal emitter radiation doses to the tissues of individual patients (patient-specific radiation dosimetry), using computer modules, are available for RIT, as well as for other radionuclide therapies. There is general agreement that radiation dosimetry (radiation absorbed dose distribution, cGy) should be utilized to establish the safety of RIT with a specific radiolabeled Ab in the early stages (i.e. phase I or II) of drug evaluation. However, it is less well established that radiation dose should be used to determine the radionuclide dose (amount of radioactivity, GBq) to be administered to a specific patient (i.e. radiation dose-based therapy). Although treatment planning for individual patients based upon tracer radiation dosimetry is an attractive concept and opportunity, particularly for multimodality RIT with intent to cure, practical considerations may dictate simpler solutions under some circumstances.

AB - Cancer-seeking antibodies (Abs) carrying radionuclides can be powerful drugs for delivering radiotherapy to cancer. As with all radiotherapy, undesired radiation dose to critical organs is the limiting factor. It has been proposed that optimization of radioimmunotherapy (RIT), that is, maximization of therapeutic efficacy and minimization of normal tissue toxicity, depends on a foreknowledge of the radiation dose distributions to be expected. The necessary data can be acquired by established tracer techniques, in individual patients, using quantitative radionuclide imaging. Object-oriented software systems for estimating internal emitter radiation doses to the tissues of individual patients (patient-specific radiation dosimetry), using computer modules, are available for RIT, as well as for other radionuclide therapies. There is general agreement that radiation dosimetry (radiation absorbed dose distribution, cGy) should be utilized to establish the safety of RIT with a specific radiolabeled Ab in the early stages (i.e. phase I or II) of drug evaluation. However, it is less well established that radiation dose should be used to determine the radionuclide dose (amount of radioactivity, GBq) to be administered to a specific patient (i.e. radiation dose-based therapy). Although treatment planning for individual patients based upon tracer radiation dosimetry is an attractive concept and opportunity, particularly for multimodality RIT with intent to cure, practical considerations may dictate simpler solutions under some circumstances.

KW - Radiation dosimetry

KW - Radioimmunotherapy

KW - Radionuclide dose

KW - Treatment dosing

UR - http://www.scopus.com/inward/record.url?scp=0034967175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034967175&partnerID=8YFLogxK

U2 - 10.1016/S1040-8428(01)00109-3

DO - 10.1016/S1040-8428(01)00109-3

M3 - Article

C2 - 11418317

AN - SCOPUS:0034967175

VL - 39

SP - 203

EP - 218

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 1-2

ER -